Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea

Allergan

Status: Completed

Conditions: Conjunctivitis, Allergic

Treatments: Drug: Alcaftadine Ophthalmic Solution 0.25%

Study type: Observational

Funder types: Industry

Identifiers

NCT02555761

229666-007

Details and patient eligibility

About

This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.

Enrollment: 3,423 patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients with itching associated with allergic conjunctivitis.

Exclusion criteria

-Patients with hypersensitivity to Lastacaft® or its components.

Trial design

3,423 participants in 1 patient group

Lastacaft®

Description:

One drop of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) in each eye daily as prescribed as standard of care in clinical practice.

Treatment:

Drug: Alcaftadine Ophthalmic Solution 0.25%